{"id":527886,"date":"2026-07-01T16:39:14","date_gmt":"2026-07-01T16:39:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/ie\/527886\/"},"modified":"2026-07-01T16:39:14","modified_gmt":"2026-07-01T16:39:14","slug":"single-fraction-sbrt-in-localized-prostate-cancer","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/ie\/527886\/","title":{"rendered":"Single-Fraction SBRT in Localized Prostate Cancer"},"content":{"rendered":"<p>&#13;<br \/>\n    \t\t  <a href=\"https:\/\/www.ascopost.com\/search-results\/?q=Matthew+Stenger\" rel=\"nofollow noopener\" target=\"_blank\">By Matthew Stenger<\/a><br \/>&#13;<br \/>\n\t\t  <a href=\"https:\/\/ascopost.com\/news\/july-2026\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>&#13;<br \/>\n\t\t  &#13;<br \/>\n\t\t  Posted: 7\/1\/2026 9:59:00 AM&#13;<br \/>\n\t\t  <br \/>&#13;<br \/>\n           Last Updated: 7\/1\/2026 11:04:44 AM&#13;<br \/>\n\t\t  &#13;\n\t\t<\/p>\n<p>&#13;<\/p>\n<p>In a phase I\/II trial reported in <a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2850672\" rel=\"nofollow noopener\" target=\"_blank\">JAMA Oncology<\/a>, Zilli et al found that single-fraction high-dose stereotactic body radiotherapy (SBRT) was associated with a high biochemical relapse\u2013free survival rate in patients with localized prostate cancer.<\/p>\n<p>Study Details<\/p>\n<p>In the trial, 43 patients with localized prostate cancer at low or intermediate risk, with International Society of Urological Pathology grade group 1 or 2, and without significant tumor in the transitional zone were enrolled at five centers in the United States and Europe between 2017 and 2022. Patients received a 19-Gy single-fraction prostate SBRT course with urethra-sparing and intrafraction motion control. The primary outcome measure was biochemical relapse\u2013free survival at 3 years, with an expected value of 96% included in the 95% confidence interval (CI).<\/p>\n<p>Key Findings<\/p>\n<p>Median follow-up was 55.3 months (interquartile range = 49.9\u201360.7 months).<\/p>\n<p>Biochemical recurrence\u2013free survival at 3 years was 92.9% (95% CI = 85.4%\u2013100%), meeting the primary endpoint; biochemical recurrence\u2013free survival at 5 years was 88.0%.<\/p>\n<p>At 3 years, grade 2 genitourinary (GU) adverse events were observed in four patients (9.8%) and grade 2 gastrointestinal (GI) adverse events were observed in two patients (4.9%). One grade 3 adverse event\u2014proctitis\u2014was observed in one patient at 12 months; no grade 4 or higher adverse events were observed. Grade 2 or higher erectile dysfunction increased from 9 (21.4%) of 42 patients at baseline to 15 (38.4%) of 39 at 3 years. A significant minimally clinically important change in Expanded Prostate Cancer Index Composite scores was observed in 6 patients (14%) for GU scores and in 12 patients (28%) for sexual scores. Minimal effects on GI bother scores were observed.<\/p>\n<p>The investigators concluded: \u201cIn this multicenter phase [I\/II] trial, a single-fraction 19-Gy urethra-sparing SBRT met the primary endpoint, achieving a 3-year [biochemical recurrence\u2013free survival] of 92.9%, with grade 2 GU and GI [adverse events] remaining below 10% and 5%, respectively, at 3 years. Longer follow-up is warranted to assess long-term disease control.\u201d<\/p>\n<p>Thomas Zilli, MD, of the Department of Radiation Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, is the corresponding author for the JAMA Oncology article.<\/p>\n<p>DISCLOSURE: The study was funded by a grant from the Fondation pour les Recherches M\u00e9dicales et Biologiques sur le Cancer and Varian Medical Systems. For full disclosures of the study authors, visit <a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/article-abstract\/2850672\" rel=\"nofollow noopener\" target=\"_blank\">jamanetwork.com<\/a>.<\/p>\n<p>&#13;<\/p>\n","protected":false},"excerpt":{"rendered":"&#13; By Matthew Stenger&#13; &#13; &#13; Posted: 7\/1\/2026 9:59:00 AM&#13; &#13; Last Updated: 7\/1\/2026 11:04:44 AM&#13; &#13; &#13;&hellip;\n","protected":false},"author":2,"featured_media":304476,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[103,61,60],"class_list":["post-527886","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-health","tag-ie","tag-ireland"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/527886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=527886"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/527886\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/304476"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=527886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=527886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=527886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}